PAR1: a potential therapeutic target for neurodegenerative processes in high-risk populations
Active Grant Awarded
- Award ID
- FAG099604UPRRG7
- Recipient
-
Mayo Clinic UEI Y2K4F9RPRRG7 Part of Mayo Clinic
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $53,114
Award facts
- Assistance listing
- 93.AG4 National Institute on Aging Training Individual Projects
- Completion date 3% complete
- Place of performance
- Rochester, MN 55905, USA
Award details come from USAspending.gov.
Description
- Abstract
- Neurodegenerative diseases are progressive, age-related disorders affecting more than 55 million people worldwide and currently lack effective disease-modifying therapies. Increasing evidence indicates that white matter (WM) degeneration and impaired remyelination are early features of neurodegeneration, including in alzheimer's disease, that occur prior to clinical symptom onset and compromise neuron integrity. However, the mechanisms that limit myelin repair remain poorly understood. This problem is particularly important in individuals carrying the APOE4 allele, the strongest genetic risk factor for late-onset alzheimer's disease, which disrupts lipid metabolism and exacerbates neuroinflammation-processes essential for efficient remyelination. Protease-activated receptor-1 (PAR1), a thrombin-activated G-protein-coupled receptor expressed in glial cells, regulates inflammatory signaling and lipid metabolism. Thrombin levels increase during neurodegeneration and are elevated in APOE4 brains. Prior work demonstrates that PAR1 signaling limits remyelination, whereas PAR1 blockade promotes myelin preservation and repair in demyelinating models, suggesting PAR1 contributes to impaired remyelination and neuronal integrity in APOE4 conditions. The central hypothesis is that PAR1 signaling limits remyelination and neuronal preservation in APOE4 conditions by promoting glial inflammation and disrupting lipid homeostasis, and that PAR1 inhibition or deletion restores myelin repair and neuronal integrity. Aim 1 will determine whether PAR1 inhibition or deletion restores remyelination and neuronal integrity in aged human APOE3 and APOE4 knock-in mice. The cuprizone model will interrogate demyelination-remyelination dynamics in 10-month-old mice. Outcomes include behavioral, histological, ultrastructural, and molecular analyses, including single-nucleus RNA sequencing (SNSEQ) to define cell type-specific mechanisms and apoe-dependent responses. Aim 2 will define how PAR1 signaling drives APOE4-associated glial dysfunction and neuronal support. Human ipsc- and mouse-derived mono- and CO-cultures of APOE3 or APOE4 astrocytes, oligodendrocytes, microglia, and neurons, along with organotypic brain slice models, will assess how PAR1 modulation regulates cholesterol homeostasis, inflammatory signaling, and myelination. Innovation: this proposal integrates aging in vivo models, human glial-neuron systems, and single-nucleus transcriptomics to define PAR1-dependent mechanisms linking lipid dysregulation and neuroinflammation to impaired remyelination in APOE4 conditions. These studies will identify PAR1 as a therapeutically actionable regulator of remyelination and neuronal preservation and provide cell-specific insight into how PAR1 modulation and apoe genotype (APOE3 VS APOE4) regulate lipid homeostasis, inflammation, and white matter regeneration.
Quick answers
Who received award FAG099604UPRRG7?
FAG099604UPRRG7 was awarded to Mayo Clinic by National Institute on Aging (National Institutes of Health) on November 16, 2026.
How much is award FAG099604UPRRG7 worth?
$53,114 has been obligated on FAG099604UPRRG7.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award